tbuckley/cabot-search huggingface dataset:
Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.
Authors: S. Z. Usmani, R. D. Bona, G. Chiosis, Z. Li
Journal: Journal of Clinical Oncology (2010)

8141 Background: PU-H71, a novel purine scaffold HSP90 inhibitor, has demonstrated anti-tumor activity in triple-negative breast cancer and Bcl6 dependent B-cell lymphoma preclinical models. Its mechanism of action is thought to be via inhibition of the cytosolic HSP90A and down regulation of its client proteins. HSP90B1 (a.k.a gp96, grp94), the endoplasmic reticulum paralogue of HSP90A, serves as a master chaperone for most integrins, which play a very important role in myeloma cell-bone marrow stromal cell interactions, cell survival and proliferation, and drug resistance. We evaluated the in vitro anti-myeloma activity of PU-H71 in human myeloma cell lines (HMCLs) and its effects on HSP90B1. Methods: Characterization of HSP90B1 and its clientele was performed in human myeloma cell lines (HMCLs) by flow cytometry and Western blotting. Stable HSP90B1 knockdown and control HMCLs were created using shRNA transduction. Drug treatments (dexamethasone, melphalan, doxorubicin, thalidomide, 17-AAG, 17DMAG and PU-H71) were performed for cell viability (trypan blue staining) and induction of apoptosis (Western blotting for anti-caspase 3). Western blotting was also performed for the unfolded protein response markers (IRE1a, XBP1, eIF2a) and the cell cycle markers (Cyclin D1,p27kip1). Results: PU-H71 has potent anti-myeloma activity with IC50 achieved in HMCLs with concentrations ≤ 100 nM at 24 hours. PU-H71 activates the unfolded protein response and increases apoptosis of HMCLs. HMCLs abundantly express HSP90B1 and show variable expression of client integrins. HSP90B1 knock-down HMCLs show less susceptibility to death when treated with PU-H71 at 24 and 48 hours. HSP90B1 knock-down HMCLs, when compared to control, demonstrate increased cell survival at lower concentrations of conventional drugs whereas more susceptibility with higher concentrations. Conclusions: The in vitro studies demonstrate that (1) PU-H71 is highly active against HMCLs; (2) PU-H71 acts by inhibiting both HSP90A and HSP90B1; (3) HSP90B1 knockdown HMCLs are more susceptible to cell death when treated with conventional myeloma drugs. Based on the results, HSP 90B1 may serve as a more specific anti-myeloma target. No significant financial relationships to disclose.
ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)—Identifying responders by subset analysis.
Authors: Sagar Lonial, Paul G. Richardson, María-Victoria Mateos, Katja Weisel, Meletios A. Dimopoulos, Philippe Moreau, Oumar Sy, Jessica Katz, Manish Gupta, Antonio Palumbo
Journal: Journal of Clinical Oncology (2016)

8037 Background: Extended follow-up of ELOQUENT-2 (NCT01239797) showed 27% reduction in risk of disease progression/death for ELd vs Ld and OS trend in favor of ELd (Dimopoulos M et al. ASH 2015; oral 28). We present subset analyses of extended 3-y follow-up. Methods: RRMM pts were randomized to ELd or Ld in 28-d cycles until disease progression/unacceptable toxicity (Lonial S et al. NEJM. 2015;373:621-31.). Coprimary endpoint: PFS. Key secondary endpoint: OS. Results: 646 pts randomized: 321 ELd, 325 Ld. Baseline demographics: median age 66 y; 32% of pts had del(17p), 9% t(4;14); median of 2 prior therapies; 35% refractory to last therapy. PFS and OS subset analyses shown in Table (data cut-off 13 Aug 2015). Median duration of response: ELd 20.3 vs Ld 16.6 mo. Conclusions: Subset analyses for ELd vs Ld were consistent with previous findings. PFS and OS benefit of ELd was seen across key subgroups, PFS benefit was durable over time. Clinical trial information: NCT01239797.PFS HR (95% CI) Median, mo (95% CI) ELd Ld Prior bortezomib Yes 0.68 (0.55–0.85) 18.5 (15.9–21.2) 12.9 (10.2–16.6) No 0.83 (0.58–1.21) 22.2 (16.6–30.3) 18.4 (13.9–22.9) Prior lenalidomide Yes 0.55 (0.24–1.25) 24.9 (12.0–NA) 7.4 (3.9–17.4) No 0.74 (0.61–0.91) 18.5 (16.5–22.2) 14.9 (12.3–17.5) del(17p)+ 0.70 (0.49–0.99); p = 0.042 21.2 (16.6–27.5) 14.9 (10.6–18.5) del(17p)- 0.73 (0.58–0.92); p = 0.007 18.5 (15.8–22.8) 14.8 (11.7–18.4) t(4;14)+ 0.52 (0.29–0.93); p = 0.027 15.8 (8.4–18.5) 5.6 (3.1–10.3) t(4;14)- 0.74 (0.60–0.91); p = 0.004 20.3 (17.3–23.3) 15.7 (13.0–18.5) Age < 65 y 0.74 (0.55–0.99); p = 0.043 19.4 (15.9–22.8) 16.6 (12.1–19.4) Age ≥ 65 y 0.72 (0.56–0.92); p = 0.009 18.5 (15.8–23.9) 13.9 (11.1–17.2) OS Risk High* 0.60 (0.37–0.97) 29.8 (22.2–NA) 24.8 (11.7–31.24) Low† 0.84 (0.28–2.52) NA (33.1–NA) 40.8 (35.2–NA) Standard 0.95 (0.72–1.26) 43.7 (40.1–NA) 47.6 (36.9–NA) del(17p)+‡ 0.66 (0.43–1.00) NA (35.8–NA) 36.4 (30.2–NA) del(17p)- 0.86 (0.66–1.14) 42.3 (36.7–NA) 40.8 (33.2–NA) Age < 65 y 0.77 (0.52–1.13) NA (42.9–NA) 40.9 (39.6–NA) Age ≥ 65 y 0.78 (0.58–1.03) 40.1 (30.5–NA) 32.2 (27.8–40.9) *ISS stage 2 or 3; t(4;14)+ or del(17p)+;†ISS stage 1 or 2; t(4;14)-, del(17p)- or 1q21-; age < 55 y; ‡≥ 1 cell del(17p)+
Comprehensive Investigation of the Molecular Mechanism of Primitive Hematopoiesis Regulating by KLF3
Authors: Zhang Zhaojun, Xiong Qian, Wang Shaobin, Wang Hai, Zhang Qian, Qi Heyuan, Li Yanming, Sun Hongying, Chang Kai-Hsin, George Stamatoyannopoulos, John A. Stamatoyannopoulos, Fang Xiangdong
Journal: Blood (2012)
Role of B-Lymphocytes in Supporting Adaptive Immune Responses Associated with the Progression of Nonalcoholic Steatohepatitis
Authors: S. Bruzzì, S. Sutti, G. Giudici, M.E. Burlone, C. Mombello, C. Bozzola, M. Pirisi, E. Albano
Journal: Journal of Hepatology (2016)
Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study)
Authors: V. Knop, J. Vermehren, J. Petersen, P. Buggisch, H. Wedemeyer, M. Cornberg, S. Mauss, M. Sprinzl, T. Berg, F. van Bömmel, H. Klinker, D. Hüppe, J.-P. Bronowicki, M. Rausch, T. Welzel, A. Vermehren, S. Susser, S. Zeuzem, C. Sarrazin
Journal: Journal of Hepatology (2016)
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Authors: Roy S. Herbst, Paul Baas, Jose L. Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary Jo Fidler, Veerle Surmont, Gilberto De Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon
Journal: Journal of Thoracic Oncology (2016)
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
Authors: David J. Pinato, Rohini Sharma, Elias Allara, Clarence Yen, Tadaaki Arizumi, Keiichi Kubota, Dominik Bettinger, Jeong Won Jang, Carlo Smirne, Young Woon Kim, Masatoshi Kudo, Jessica Howell, Ramya Ramaswami, Michela E. Burlone, Vito Guerra, Robert Thimme, Mitsuru Ishizuka, Justin Stebbing, Mario Pirisi, Brian I. Carr
Journal: Journal of Hepatology (2016)
PTU-023 The use of argon plasma coagulation to prevent colorectal polyp recurrence following piecemeal endoscopic mucosal resection: Abstract PTU-023 Table 1
Authors: A Chattree, MD Rutter
Journal: Gut (2015)

<h3>Introduction</h3> High levels of recurrence and residual tissue have been reported following piecemeal endoscopic resection (pEMR) of large colorectal polyps with figures approaching 30% described.<sup>1</sup>The application of argon plasma coagulation (APC) has been advocated to reduce recurrence following pEMR, with early data appearing to support the use of APC to treat tiny polyp fragments not amenable to endoscopic snare resection.<sup>2</sup>More recent data however, appears to oppose this view, suggesting no change in or even increased recurrence following adjunctive APC use.<sup>1</sup>With a lack of standardised APC application in relevant international case series, many of which include only small sample sizes, the position regarding its benefit remains controversial. <h3>Method</h3> Retrospective analysis was conducted on 153 pEMR procedures undertaken in the Bowel Cancer Screening Programme (BCSP) between 2011–12. Recurrence rates on first endoscopic follow-up were compared between 2 groups (APC use vs no APC use). Statistical analysis was performed using the chi-squared test. <h3>Results</h3> Recurrence was detected on first endoscopic follow-up in 25.5% of cases. A lower level of recurrence was seen in the APC group compared with the non APC group (17.9% vs 31.4%), with statistical significance seen on 1-sided but not 2-sided chi square analysis (p = 0.042 (1-sided), p = 0.064 (2-sided)) <h3>Conclusion</h3> While statistical significance was only seen on 1-sided chi-square analysis, the level of recurrence was over 40% lower in the APC group (17.9% vs 31.4%). It can be argued that our study may be underpowered and that the result indicates likely clinical significance. Our data does not support the data from other studies indicating a possible detrimental effect of APC. Whilst the use of APC is likely to be more standardised within the BCSP, the exact circumstances of its use, such as the amount of residual tissue post snare resection remaining prior to APC use in other studies, is unclear. We believe APC is appropriate therapy for tiny residual polyp fragments post snare resection, but should not be used on larger tissue areas. A large randomised controlled trial with a standardised protocol for APC application would add further evidence. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Moss A, Bourke MJ, Williams SJ, <i>et al</i>. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology 2011;140:1909–18 Brooker JC, Saunders BP, Shah SG, <i>et al</i>. Treatment with argon plasma coagulation reduces recurrence after piecemeal resection of large sessile colonic polyps: a randomized trial and recommendations. Gastrointest Endosc. 2002;55:371–5
Neoadjuvant chemotherapy in cervical cancer patients: a single institution experience.
Authors: Matilde Destefanis, Marco Filippeschi, Giuditta Zipoli, Patrizia Dentico, Massimo Gabbanini, Maria Teresa Gemelli, Pier Giorgio Giannessi, Andrea Muto, Susanna Rossi, Gina Turrisi, Carlo Milandri
Journal: Journal of Clinical Oncology (2016)

e17020 Background: Cervical cancer is the fifth cancer for incidence in Italy . Surgery is usually reserved for small lesions (stage IA-IB1). Chemoradiation is the preferred treatment for stage IB2 to IVA disease. The goal of this abstract is to present our institute datas and discuss the role of neoadjuvant chemotherapy in locally advanced cervical cancer. Methods: Between 2010 and 2015 we treated 18 patient for locally advanced cervical cancer. Only 10 patients were evaluable for retrospective analysis. Median age was 42 years. Patients with histologically confirmed locally advanced cervical cancer (FIGO IB2-IVA) were selected to riceive TIP regimen . Biopsy histology included n = 9 squamous cell carcinoma and n = 1 adenosquamous cell cancer. Chemotherapy was administered as follows: paclitaxel at the dose of 175 mg/m2 on day 1, cisplatin 50 mg/m2 on day 2. After cisplatin a bolus of mesna 300 mg/m2 was given followed by ifosfamide 5g/m2 and mesna 5 g/m2 infused during 24 hours and subsequently followed by mesna 3 gr/m2during 24 hours. The treatment was administered every 3 weeks for a maximum of three cycles. Results: Common toxicities reported were: nausea and vomiting, febrile neutropenia, hyperglycemia, thrombocytopenia. All the patients showed a clinical response and underwent radical hysterectomy plus pelvic lymphadenectomy. Pathological response after surgery resulted as follows: 4 of 10 patients had a suboptimal response (more than 3 mm stromal invasion), 3 patients had a minimal residual disease (less than 3 mm invasion and pTis) and 1 patient had a complete response. Two patients showed a worse pathological stage after surgery and aggressive hystology. Women with suboptimal response, positive nodes or parametrial involvement were evaluated for adjuvant treatment: 1 patient received adjuvant chemoterapy, 1 patient received pelvic irradiation plus brachytherapy and 5 patients received exclusive pelvic irradiation. Conclusions: Neoadjuvant chemoterapy followed by radical surgery has resulted in high clinical responses rates and it also seems to be a feasible treatment in the management of locally advanced cervical cancer. We believe this could represent a valid alternative to primary chemoradiation in young patients.
Shared Governance Embedded in Population Ethics Can Enhance Health Equity Research at Both Micro and Macro Levels
Authors: Stephen O. Sodeke, Clayton C. Yates
Journal: The American Journal of Bioethics (2016)

In their article, “Governance of Transnational Global Health Research Consortia and Health Equity,” Pratt and Hyder (2016) proposed four ethical requirements connected to shared health governance i...
Getting Pharmacogenomics Into the Clinic
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caecal ulceration in an asymptomatic man
Authors: Nan Wu, John Saul Freiman
Journal: Gut (2016)

A 66-year-old Caucasian man underwent bowel cancer screening colonoscopy. He was asymptomatic with no significant medical history and no family history of bowel cancer or IBD. Clinical examination was normal and routine blood tests including haematinics, renal function, electrolytes and liver function were normal. Colonoscopy revealed several shallow periappendiceal caecal ulcers (figure 1). CT revealed caecal thickening with a few small para-caecal lymph nodes. The liver, spleen, small intestine and remaining colon were normal (figure 2).



Figure 1 
Caecal ulcer …
Abstract 4704: Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma
Authors: Sander Kelderman, Laura Bies, Marit M. Van Buuren, Nienke Van Rooij, John Haanen, Pia Kvistborg, Ton Schumacher
Journal: Cancer Research (2015)

Abstract The mutational load in melanoma is high relative to that in most other human malignancies, resulting in the possible expression of large numbers of patient-specific mutated antigens. This may, in part, explain the immunogenicity of this disease and the high rate of responsiveness to immunotherapeutic strategies such as tumor-infiltrating lymphocyte (TIL) therapy. Indeed, recent data have shown that cytotoxic T-cell reactivity targeting neo antigens may be common in human melanoma TILs. Importantly though, the clinical relevance of neo-antigen specific T cell populations remains uncertain. To directly address the tumoricidal potential of defined neo-antigen specific T cell populations, we first identified two neo-antigen specific T-cell populations within a bulk melanoma TIL culture by the combination of exome sequencing and MHC multimer-based T cell screens. Subsequently, we generated TIL products that are highly enriched for these neo-antigen reactivities and we compared the anti-tumor activity of these neo-antigen enriched TIL with that of ‘standard’ bulk TIL in NSG mice bearing the autologous tumor. We observed outgrowth of the tumors in mice treated with standard TIL. In contrast, tumors in mice treated with enriched TILs were controlled long-term. Additional experiments showed that this superior activity of neo-antigen enriched TIL was caused by the increased numbers of T cells with a high anti-tumor activity, rather than the depletion of cell populations with inhibitory activity. Furthermore, once tumors eventually recurred these were still recognized in vitro by cells from the initially infused TIL culture. Together, these preclinical data demonstrate that neo-antigen reactive T cells within bulk TIL cultures form a critical component of anti-tumor reactivity and provide a further basis to target mutated antigens with cancer immunotherapy. Citation Format: Sander Kelderman, Laura Bies, Marit M. Van Buuren, Nienke Van Rooij, John Haanen, Pia Kvistborg, Ton Schumacher. Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4704. doi:10.1158/1538-7445.AM2015-4704
Use of quantitative proteomics to evaluate substrates and functional modules of the aurora and polo-like kinases.
Authors: S. A. Gerber, A. N. Kettenbach, D. K. Schweppe, K. H. Dragnev, J. R. Rigas
Journal: Journal of Clinical Oncology (2010)

e13530 Background: Protein kinases are rapidly emerging as an important class of targets for cancer chemotherapy, including the mitotic kinases Aurora A, Aurora B, and Polo-like kinase 1 (Plk1), which are frequently overexpressed in many solid tumors. In this work, we mapped in vivo phosphorylation sites to these three kinases through the use of innovative methods in quantitative proteomics. Using our approach, we connected 815 phosphorylation sites on 609 proteins to the specific activities of these three kinases in preclinical model systems. Methods: HeLa cells in culture were arrested in mitosis and treated separately with the selective kinase inhibitors MLN8054, AZD1152, and BI2536 to inhibit the activity of the Aurora A, Aurora B, and Plk1 enzymes, respectively. Subsequently, the phosphoproteomes of these treated cells were compared to control cells using stable-isotope labeling methods in quantitative proteomics. Inhibition of enzyme activity resulted in a decrease in the relative intensities of substrate phosphorylation sites relative to the control when analyzed by mass spectrometry. Results: Using bioinformatics methods, we classify 115, 157, and 543 phosphorylation loci as substrates of Aurora A, Aurora B, and Plk1, respectively. We observe distinct linear motifs for each of these datasets which recapitulate previous reports of consensus motifs for each kinase, but also extend the motif elements and in some cases generate new substrate motifs. We observe cross-regulation of Plk1 and Aurora A with each other, but not with Aurora B. Furthermore, we find novel substrate classes that suggest potential roles for these kinases in oncogenesis. Conclusions: This work has uncovered new functional roles, established novel substrate recognition motifs, and generated a subset of candidate biomarkers and additional entry points for therapeutic intervention for these clinically relevant cancer targets. In addition, our approach provides an analytical template for further use in dissecting other kinase signaling events in translational research. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Boehringer Ingelheim Millennium
Model for Endstage Liver Disease (MELD) Score Changes during Hepatitis C Virus Treatment of Patients with Cirrhosis Predicts Long-Term Portal Hypertensive Complications
Authors: V. Saxena, L. Nyberg, A. Dasgupta, S. Straley, L. Catalli, A. Nyberg, N. Terrault
Journal: Journal of Hepatology (2016)
How has early invasive breast cancer (BC) changed in the past decade? Analysis of 3615 consecutive patients (pts)
Authors: M. Giovannini, A. Mercanti, E. Fiorio, A. Auriemma, M. Mandara’, M. Frisinghelli, M. Pavarana, R. Micciolo, G. L. Cetto, A. Molino
Journal: Journal of Clinical Oncology (2005)

688 Background: The aim of our study was to highlight any time related changes in BC characteristics and surgical management of 3615 pts with early invasive tumours T1-T3 collected from 1992 to 2002 in Verona (Italy). Methods: We considered tumour size (T1, T2, T3), nodal involvement (N0, N1–3, N4–10, N>10), Grading (G1, G2, G3); Ki-67 (0–25%, 26–100%); ER, PgR, p21, p53, c-erbB2, BCL2 (-ve/+ve) and vascular invasion; age at diagnosis (< and > 50 years), modality of diagnosis (asymptomatic/symptomatic), type of surgery (conservative/radical), axillary dissection, number of examined nodes (N0–10, N>10) and reconstruction. Results: BC diagnosed more recently were smaller (T1: 54.9% in ’92 vs 74.9% in ’02; T2: 41.9% in ’92 vs 22.4% in ’02, p< 0.001) and among T1, T<10 mm were more frequent (19.5% in ’92 vs 32.8% in ’02; p<0.001); with lower nodal involvement (N0: 58.3% in ’92 vs 62.6% in ’02; p=0.02); higher Grading (G3: 24.4% in ’92 vs 28.9% in ’02; p=0.005); higher proliferation rate (Ki-67 > 25%: 11.9% in ’92 vs 14.5% in ’02; p<0.004); more frequently PgR+ve (34.4% in ’92 vs 68.9% in ’02; p<0.001); c-erbB2-ve (65.7% in ’94 vs 43.4% in ’02, p<0.001), p53-ve (66.7% in ’95 vs 86.2% in ’02; p<0.001) and with absence of vascular invasion (56% in ’97 vs 70.7% in ’02; p=0.04); no differences were seen in ER+ve, BCL2 and p21. Women with recently diagnosed early invasive BC were younger (< 50 years: 25.1% in ’92 vs 27.8% in ’02; p=0.01) and more frequently asymptomatic at diagnosis (22.1% in ’92 vs 52.5% in ’02; p<0.001). Conservative surgery increased (34% in ’92 to 77.4% in ’02; p<0.001); complete axillary dissection decreased (95.8% in ’92 vs 52.7% in ’02; p<0.001) with fewer examined nodes (N0–10: 20.5% in ’92 vs 25.6% in ’02; p<0.001) and reconstruction increased (40.2% in ’92 vs 90% in ’02; p<0.001). Conclusions: Some of our results seem to indicate that more recently diagnosed BC have better characteristics, possibly because of the introduction of screening in July ’99 (T1, N0, no vascular invasion); others indicate worse characteristics (higher Ki-67, more G3) possibly because of the younger age at diagnosis. Complete axillary dissection decreased since the introduction of sentinel node approach. No significant financial relationships to disclose.
Doctors are working five unpaid extra weeks a year, claim leaders
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Some doctors are working an extra five weeks a year for no extra money owing to relentlessly growing demand and understaffing, the Royal College of Physicians has said.

The college published a report on 21 September in which it made several stark warnings about the extreme pressures currently on the NHS.1

The report was based on the latest national data for the NHS and drew on the experiences, views, and concerns of consultant and trainee physicians surveyed for the college. It painted a picture of an NHS struggling to cope under the increasing …
High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I)
Authors: E. Gane, F. Poordad, A. Asatryan, J. Lalezari, T. Hassanein, H. Aguilar, T.I. Ng, Ran Liu, C.-W. Lin, J. Kort, F. Mensa
Journal: Journal of Hepatology (2016)